Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms. We analyzed the changes in frequency and severity of menopausal symptoms in patients receiving tamoxifen or aromatase inhibitors and identified factors influencing these symptoms. One hundred and eighty-one consecutive postmenopausal breast cancer patients scheduled to start endocrine treatment were included in this prospective study. A menopause symptom questionnaire covering vasomotor, atrophic, psychological, cognitive and somatic symptoms was filled in at baseline, and after 1 and 3 months of therapy. Both first-line tamoxifen and aromatase inhibitors induced an increase in the occurrence and severity of hot flashes (p<0.0001 and p=0.014, respectively). Musculoskeletal pain and dyspareunia significantly increased under first-line non-steroidal aromatase inhibitors (p=0.0039 and p=0.001, respectively), while patients under tamoxifen had significant decrease in sexual interest (p< or =0.0001). Younger age was associated with more hot flashes and vaginal dryness at baseline, and after 1 and 3 months of therapy (all p<0.02). We conclude that there are significant differences between the early effects of tamoxifen and aromatase inhibitors on menopausal symptoms of breast cancer patients. Our results underscore the need for safe and effective non-hormonal interventions to alleviate vasomotor and musculoskeletal symptoms which were the most prevalent and severe symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Prospective evaluation of vitamin E for hot flashes in breast cancer survivors.
Barton, D. L., Loprinzi, C. L., Quella, S. K., Sloan, J. A., Veeder, M. H., Egner, J. R., Fidler, P., Stella, P. J., Swan, D. K., Vaught, N. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.495 · Cited by 403
Cited by
Kendall, A., Dowsett, M., Folkerd, E., & Smith, I. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj127 · Cited by 277
Sexuality and Fertility after Cancer
Schover, L. R. (2005) · Hematology · doi:10.1182/asheducation-2005.1.523 · Cited by 257
Mar Fan, H. G., Houédé-Tchen, N., Chemerynsky, I., Yi, Q.-L., Xu, W., Harvey, B., & Tannock, I. F. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp394 · Cited by 71
Efficacy of a biobehavioral intervention for hot flashes: a randomized controlled pilot study
Barton, D. L., Schroeder, K. C. F., Banerjee, T., Wolf, S., Keith, T. Z., & Elkins, G. (2017) · Menopause · doi:10.1097/gme.0000000000000837 · Cited by 27
Labrie, F., & Martel, C. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0042 · Cited by 17
Metadata
- Authors
- Morales, L., Neven, P., Timmerman, D., Christiaens, M.-R., Vergote, I., Van Limbergen, E., Carbonez, A., Van Huffel, S., Ameye, L., & Paridaens, R.
- Venue
- Anti-Cancer Drugs
- Published
- 2004-09
- Volume
- 15
- Issue
- 8
- Pages
- 753-760
- ISSN
- 0959-4973 (ISSN-L)
- OpenAlex
- W2066447617
- Cited by
- 144
- References
- 2
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. https://app.cochat.ai/papers/10.1097/00001813-200409000-00003
- The paper
- Morales, L., Neven, P., Timmerman, D., Christiaens, M.-R., Vergote, I., Van Limbergen, E., Carbonez, A., Van Huffel, S., Ameye, L., & Paridaens, R. (2004). Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anti-Cancer Drugs. https://doi.org/10.1097/00001813-200409000-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.